SEC 13F Intelligence

Morgens Waterfall Vintiadis & Co Inc / REGN

Morgens Waterfall Vintiadis & Co Inc’s Regeneron Pharmaceuticals Position

Does Morgens Waterfall Vintiadis & Co Inc own Regeneron Pharmaceuticals (REGN)? Not currently — the last reported position was 3.3K shares worth $3M in Q3 2024; the fund’s latest 13F (Q1 2026) no longer reports it.

Position Value
$3M
Q3 2024
Shares
3.3K
% of Portfolio
+2.69%
Quarters Held
12
position exited

Position History REGN

Reported value by quarter
Q2 ’21: $2MQ2 ’21Q3 ’21: $2MQ1 ’22: $3MQ1 ’22Q3 ’22: $758,000Q4 ’22: $1MQ4 ’22Q1 ’23: $1MQ2 ’23: $1MQ2 ’23Q3 ’23: $1MQ4 ’23: $4MQ4 ’23Q1 ’24: $4MQ2 ’24: $3MQ2 ’24Q3 ’24: $3Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q3 20243.3K$3M+2.69%
Q2 20243.3K$3M+2.64%
Q1 20243.9K$4M+2.59%
Q4 20234.1K$4M+2.68%
Q3 20231.5K$1M+1.00%
Q2 20231.5K$1M+0.77%
Q1 20231.5K$1M+1.01%
Q4 20221.5K$1M+0.94%
Q3 20221.1K$758,000+0.83%
Q1 20223.9K$3M+1.71%
Q3 20213.5K$2M+1.09%
Q2 20213.5K$2M+1.00%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Morgens Waterfall Vintiadis & Co Inc’s full portfolio or all institutional holders of REGN.